Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
EP2-R52H5 | Rat | Rat EphA2 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
EP2-H82E4 | Human | Biotinylated Human EphA2 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Biotinylated Human EphA2 Protein, His,Avitag (Cat. No. EP2-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human Ephrin-A1, Fc Tag (Cat. No. EF1-H5251) with a linear range of 0.1-1 ng/mL (QC tested).
The purity of Rat EphA2 Protein, His Tag (Cat. No. EP2-R52H5) is more than 90% and the molecular weight of this protein is around 50-65 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
Dasatinib Hydrate | BMS-354825; XS-004; NSC-732517 | Approved | Bristol-Myers Squibb Company | Spraysel, 施达赛, Dasynoc, Spricel, Sprycel | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Bristol-Myers Squibb Company | 2006-06-28 | Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leukemia; Liver Neoplasms; Hematologic Neoplasms; Hypereosinophilic Syndrome; Solid tumours; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Bone metastases; Skin Melanoma; Rhabdomyosarcoma; Chondrosarcoma; Immunoproliferative Small Intestinal Disease; Ovarian Neoplasms; Leukemia, Myeloid; Cystadenocarcinoma; HIV Infections; Rectal Neoplasms; Polycythemia Vera; Leukemia, Lymphoid; Leukemia, Hairy Cell; Hormone-Resistant Prostate Neoplasms; Idiopathic Pulmonary Fibrosis; Colonic Neoplasms; Neoplasms; Salivary Gland Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Scleroderma, Systemic; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Mastocytosis, Systemic; Leukemia-Lymphoma, Adult T-Cell; Hodgkin Disease; Carcinoma, Verrucous; Lymphoma, Large-Cell, Immunoblastic; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (C | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
BT-5528 | BT-5528; BT5528 | Phase 2 Clinical | Bicycle Therapeutics | Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
siRNA-EphA2-DOPC | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms | Details | |
18F-Dasatinib | 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Lymphoma; Diagnostic agents; Melanoma | Details |
SC-102 | SC-102 | Phase 1 Clinical | Tianjin Conjustar Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) | Phase 1 Clinical | California Institute For Regenerative Medicine, National Cancer Institute | Glioblastoma | Details |
This web search service is supported by Google Inc.